样式: 排序: IF: - GO 导出 标记为已读
-
Factor XI: structure, function and therapeutic inhibition J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-04-16 Ahmed E. Ali, Richard C. Becker
-
Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-04-13 Angelo Silverio, Michele Bellino, Fernando Scudiero, Tiziana Attisano, Cesare Baldi, Angelo Catalano, Mario Centore, Arturo Cesaro, Marco Di Maio, Luca Esposito, Giovanni Granata, Francesco Maiellaro, Iacopo Muraca, Giuseppe Musumeci, Guido Parodi, Davide Personeni, Renato Valenti, Carmine Vecchione, Paolo Calabrò, Gennaro Galasso
-
Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-04-06 Meghan E. Peterson, Megan P. Jaynes, Sarah Berardi, Colleen Morton
-
Thromboembolic events after major bleeding events in patients with mechanical heart valves: a 13-year analysis J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-31 Pascal Augustin, Stefan Andrei, Bernard Iung, Marylou Para, Peter Matthews, Christian de Tymowski, Nadine Ajzenberg, Philippe Montravers
Anticoagulation in patients with mechanical heart valves (MHV) is associated with a risk of major bleeding episodes (MBE). In case of MBE, anticoagulant interruption is advocated. However, there is lack of data regarding the thrombo-embolic events (TE) risk associated with anticoagulant interruption. The main objective of the study was to evaluate the rate and risk factors of 6-months of TEs in patients
-
Management of DOAC-related bleeding in cancer patients: a single center-case series J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-31 Sophia Lee, Jeremy A. Ross, Ali Zalpour, Jason T. Henry, Cristhiam M. Rojas Hernandez
Venous thromboembolism (VTE) and stroke carry significant mortality and morbidity in cancer patients. Direct oral anticoagulants (DOACs) have been demonstrated to be effective for the treatment of VTE and prevention of stroke in atrial fibrillation (AF). Bleeding rates are variable and are based on the cancer type and the patient’s specific risk factors. There are approved specific antidotes for DOAC-associated
-
Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-31 Yee-Jen Wu, Chien-Chih Wu, Hsin-Yi Huang, Chi-Yun Wu, Ching-Chang Huang, Chi-Chuan Wang
Low-dose prasugrel demonstrated a similar effectiveness profile to clopidogrel in East Asian ACS patients, but its comparison with another new-generation potent P2Y12 inhibitor, ticagrelor, remains unclear. To compare the effectiveness and safety of low-dose prasugrel against those of standard-dose ticagrelor in East Asian patients with ACS. This retrospective cohort study used Taiwan’s National Health
-
Impact of rise and fall phases of shear on platelet activation and aggregation using microfluidics J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-31 Xuemei Gao, Tiancong Zhang, Xiaojing Huang, Xuanrong Huan, Yuan Li
Blood flow disorders are often the result of the non-physiological narrowing of blood arteries caused by atherosclerosis and thrombus. The blood then proceeds through rising-peak-decreasing phases as it passes through the narrow area. Although abnormally high shear is known to activate platelets, the shear process that platelets undergo in small arteries is complex. Thus, understanding how each shear
-
One-year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after acute large vessel occlusion stroke J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-31 Yasutaka Murakami, Kenichi Todo, Kazutaka Uchida, Hiroshi Yamagami, Nobuyuki Sakai, Yasufumi Gon, Shuhei Okazaki, Tsutomu Sasaki, Shinichi Yoshimura, Takeshi Morimoto, Hideki Mochizuki
Although low-dose direct oral anticoagulants (DOACs) are recommended for patients at high risk of bleeding complications, it remains unclear whether the dose reduction in real-world setting is also appropriate in patients after large-vessel occlusion (LVO) stroke. This study hypothesized that patients with atrial fibrillation (AF) and LVO receiving low-dose DOACs have an increased risk of ischemic
-
Management of direct oral anticoagulant drug interactions in hospitalized patients J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-30 Mohsen H. Al Zaria, Leo F. Buckley, Heather Dell’orfano, Peter Manzo, John Fanikos
Moderate-strong CYP3A4 or Pgp inhibitors and inducers alter direct oral anticoagulant (DOAC) pharmacokinetics. Whether the presence of a DOAC drug-drug interaction (DDI) prompts in- hospital changes in management remains unknown. We identified all hospitalized patients at our institution who were admitted with a clinically relevant DOAC DDI from 01/2021 to 06/2021. Clinically relevant DOAC DDIs were
-
Persistent hypofibrinolysis in severe COVID-19 associated with elevated fibrinolysis inhibitors activity J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-25 Erica Okazaki, Bárbara Gomes Barion, Tania Rubia Flores da Rocha, Giovanna Di Giacomo, Yeh-Li Ho, Cynthia Rothschild, Giancarlo Fatobene, Bruna del Guerra de Carvalho Moraes, Bianca Stefanello, Paula Ribeiro Villaça, Vanderson Geraldo Rocha, Fernanda Andrade Orsi
-
COVID-19 vaccination affects short-term anti-coagulation levels in warfarin treatment J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-25 Li-Hua Liu, Yang-Zhao Zhou, Tian-Yu Li, Da-Bin Kuang, Qun Liang, Lei Chen, Da-Feng Yang, Xia Zhang, Sheng-Lan Tan
-
Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-20
Abstract Oral anticoagulants (OACs) are recommended for patients with atrial fibrillation (AFib) having CHA2DS2-VASc score ≥ 2. However, the benefits of OAC initiation in patients with AFib and cancer at different levels of CHA2DS2-VASc is unknown. We included patients with new AFib diagnosis and a record of cancer (breast, prostate, or lung) from the 2012–2019 Surveillance, Epidemiology, and End Results
-
Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-16 Omri Cohen, Gili Kenet, Sarina Levy-Mendelovich, Inna Tzoran, Benjamin Brenner, Cristina De Ancos, Patricia López-Miguel, José F. Varona, Judith Catella, Manuel Monreal
While direct oral anticoagulants (DOACs) are frequently used to treat venous thromboembolism (VTE), the outcomes of patients with inherited thrombophilia (IT) receiving DOACs for VTE remain understudied. We used data from the international RIETE registry to compare the rates of VTE recurrences, major bleeding, and mortality during anticoagulant treatment in VTE patients with and without IT, grouped
-
Antithrombotic strategies for preventing graft failure in coronary artery bypass graft J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-16 Maria Sara Mauro, Simone Finocchiaro, Dario Calderone, Carla Rochira, Federica Agnello, Lorenzo Scalia, Davide Capodanno
-
Superficial vein thrombosis and its relationship with malignancies: a prospective observational study J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-16 Alejandro Díez-Vidal, Javier Gómez López, Pablo Rodríguez Fuertes, Fabián Tejeda Jurado, Paula Berrocal Espinosa, Juan Francisco Martínez Ballester, Sonia Rodríguez Roca, María Angélica Rivera Núñez, Ana María Martínez Virto, Yale Tung-Chen
-
Prediction of mortality in acute pulmonary embolism in cancer-associated thrombosis (MAUPE-C): derivation and validation of a multivariable model J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-14 Mario Aramberri, Jesús González-Olmedo, Adrián García-Villa, Ane Villanueva, Cristina Castillo Maza, Susana García-Gutiérrez, Carmen Diaz-Pedroche
-
Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-13 Paul A. Gurbel, Kevin Bliden, Matthew Sherwood, Hamid Taheri, Behnam Tehrani, Marjaneh Akbari, Shahram Yazdani, Juzer Ali Asgar, Rahul Chaudhary, Udaya S. Tantry
-
Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-13 Julius Chacha Mwita, Joel Msafiri Francis, Chriselda Pillay, Okechukwu S. Ogah, Dejuma Yadeta Goshu, Francis Agyekum, John Mukuka Musonda, Maduka Chiedozie James, Endale Tefera, Tsie Kabo, Keolebile Irene Ditlhabolo, Kagiso Ndlovu, Ayoola Yekeen Ayodele, Wigilya P. Mkomanga, Pilly Chillo, Albertino Damasceno, Aba Ankomaba Folson, Anthony Oyekunle, Erius Tebuka, Fredrick Kalokola, Karen Forrest, Helena
-
The incidence of major bleeding in adult patients with urogenital and gynecological cancer being treated with direct oral anticoagulants (DOACs): a systematic review J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-03-01 L. Al-Tourah, S. Mithoowani, W Lim, Rick Ikesaka
-
Discrimination of the acute pulmonary embolism subtypes based on the novel MAPH score J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-28 Onur Akhan, Mustafa Boz, Tuncay Guzel, Mehmet Kis
-
Is a minimum duration of 5 days of unfractionated heparin infusion necessary before transition to oral anticoagulation in cerebral venous thrombosis? a retrospective chart review J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-28
Abstract In managing cerebral venous sinus thrombosis (CVT), the standard approach has been administering parenteral anticoagulation for at least five days, despite limited supporting evidence. This study aimed to determine the optimal duration of parenteral anticoagulation for CVT patients and its potential impact on their functional outcomes upon discharge. This retrospective observational cohort
-
Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-26
Abstract Background Direct oral anticoagulants (DOACs) are the preferred treatment for venous thromboembolism (VTE). However, DOAC use in patients with a BMI greater than 40 kg/m2 has not been well studied despite the growing prevalence of obesity, and current literature is often underpowered. Methods This multicenter, retrospective, observational study evaluated patients 18 years and older who received
-
A systematic review of therapeutic enoxaparin dosing in obesity J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-25 Maya R. Chilbert, Kimberly Zammit, Uzma Ahmed, Amanda Devlin, Sara Radparvar, Ashley Schuler, Ashley E. Woodruff
-
Impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease patients complicated with end-stage renal disease J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-23 Zekang Ye, Qin Wang, Inam Ullah, Qingxia Lin, Tianyu Wu, Mingwen Yang, Yuansheng Fan, Zhou Dong, Tong Wang, Jianzhen Teng, Rui Hua, Yingdan Tang, Yule Li, Xiaoxuan Gong, Liang Yuan, Zhengxian Tao, Chunjian Li
-
A ten-year comparison of treatment and outcomes of cancer-associated thrombosis to non-cancer venous thromboembolism: from traditional anticoagulants to direct oral anticoagulants J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-23
Abstract DOACs have emerged as first-line treatment in most cancer-associated thrombosis (CAT), representing a paradigm shift in its management. However, CAT management remains challenging and requires careful risk–benefit considerations. A retrospective analysis of CAT presentations to a tertiary referral centre from January 2011 to December 2020. Outcomes in CAT patients were compared to VTE patients
-
Effect of continuous 2 MHz transcranial ultrasound as an adjunct to tenecteplase thrombolysis in acute anterior circulation ischemic stroke patients: an open labeled non-randomized clinical trial J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-23 Semparuthi Arumugham, Sunil K. Narayan, Rajeswari Aghoram
-
Therapeutic implication of MicroRNA-320a antagonist in attenuating blood clots formed during venous thrombosis J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-23 Swati Srivastava, Iti Garg, Nilanjana Ghosh, Rajeev Varshney
-
Blood group AB is associated with reduced blood loss but also elevated cardiovascular mortality in aortocoronary bypass surgery J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-12 Franz Masseli, Arlinda Veseli, Marvin Pfohl, Jochen Hoch, Hendrik Treede, Wolfgang Schiller
-
Low on-clopidogrel ADP- and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-12 Diona Gjermeni, Viktoria Anfang, Hannah Vetter, Sofia Szabó, David Hesselbarth, Nadine Gauchel, Patrick M. Siegel, Klaus Kaier, Alexander Kille, Kilian Franke, Stefan Leggewie, Dietmar Trenk, Daniel Duerschmied, Christoph Bode, Dirk Westermann, Christoph B. Olivier
-
Remote intensive management to improve antiplatelet adherence in acute myocardial infarction: a secondary analysis of the randomized controlled IMMACULATE trial J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-02-01 Hui Wen Sim, Karen W. L. Koh, Sock-Cheng Poh, Siew Pang Chan, Stephanie Marchesseau, Devinder Singh, Yiying Han, Faclin Ng, Eleanor Lim, Joseph F. Prabath, Chi-Hang Lee, Ruth Chen, Leonardo Carvalho, Sock-Hwee Tan, Joshua P. Y. Loh, Jack W. C. Tan, Karishma Kuwelker, R. M. Amanullah, Chee-Tang Chin, James W. L. Yip, Choy-Yee Lee, Juvena Gan, Chew-Yong Lo, Hee-Hwa Ho, Derek J. Hausenloy, Bee-Choo Tai
-
Proteomics associated with coronary high-risk plaques by optical coherence tomography J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-31
Abstract Biomarkers are widely used for the diagnosis and monitoring of cardiovascular disease. However, markers for coronary high-risk plaques have not been identified. The aim of this study was to identify proteins specific to coronary high-risk plaques. Fifty-one patients (71.2 ± 11.1 years, male: 66.7%) who underwent intracoronary optical coherence tomography imaging and provided blood specimens
-
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-28
Abstract Background In patients with atrial fibrillation (AF) and normal or slightly impaired renal function, the use of direct oral anticoagulants (DOACs) is preferable to vitamin K antagonists (VKAs). However, in patients undergoing hemodialysis, the efficacy, and safety of DOACs compared with VKAs are still unknown. Purpose To review current evidence about the safety and efficacy of DOACs compared
-
Computed tomography-based radiomics model to predict adverse clinical outcomes in acute pulmonary embolism J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-28 Fei Yang, Rong Chen, Yue Yang, Zhixiang Yang, Yaying Su, Mengmeng Ji, Zhiying Pang, Dawei Wang
-
Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-28
Abstract To evaluate the safety of direct oral anticoagulants (DOACs) versus low-molecular weight heparin (LMWH) in patients with central nervous system (CNS) malignancies and secondary metastases. All adult patients with CNS malignancies and secondary metastases who were treated with a DOAC or LMWH for any indication from 2018 to 2022 were included. The primary outcome was the incidence of any intracranial
-
Trends of Pulmonary Embolism-Related Sudden Cardiac Death in the United States, 1999–2019 J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-28 Marco Zuin, Thure Filskov Overvad, Ida Ehlers Albertsen, Claudio Bilato, Gregory Piazza
-
Treating periprocedural bleeding in patients with cirrhosis J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-28 Antoni Sabate, Ecaterina Scarlatescu
-
Prospective analysis of pre and postoperative laboratory parameters associated with thrombosis in patients with ovarian cancer J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-28 Hyoeun Shim, Ji Hyun Kim, Dong-Eun Lee, Mi Hyang Kwak, Sang Yoon Park, Myong Cheol Lim, Sun-Young Kong
-
Different drugs in drug-eluting stents for peripheral artery disease: a systematic evaluation and Bayesian meta-analysis J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-28 Keqin Chen, Lei Xu, Xiehong Liu
-
Association between changed self-rated health and the risk of venous thromboembolism in Malmö Preventive Program: a cohort study J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-24 Peter Nymberg, Veronica Milos Nymberg, Susanna Calling, Gunnar Engström, Peter Svensson, Johan Elf, Bengt Zöller
-
Short-term antiplatelet versus anticoagulant therapy after left atrial appendage closure: a systematic review and meta-analysis J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-05
Abstract This meta-analysis compared the efficacy and safety of different antithrombotic regimens after left atrial appendage closure (LAAC). PubMed, Embase, Medline, Cochrane Library databases were systematically searched from their inception to March 2023. Patients were divided into short-term oral anticoagulation (OAC) group and antiplatelet therapy (APT) group. The incidence of events were performed
-
Effects of elevated remnant cholesterol on outcomes of acute ischemic stroke patients receiving mechanical thrombectomy J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2024-01-05 Mengmeng Li, Meng Wang, Yixin Zhao, Rui Zhong, Wanying Chen, Xiangyu Lei, Xiaoyu Wu, Jiaxin Han, Lei Lei, Qingfan Wang, Guogang Luo, Meng Wei
-
Elevated factor XI is associated with increased risk of recurrent cerebral venous sinus thrombosis: a cohort study J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-25 Elżbieta Paszek, Maciej Polak, Anetta Undas
-
Outcomes of mechanical thrombectomy in acute stroke patients with atrial fibrillation detected after stroke versus known atrial fibrillation J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-21 Lucio D’Anna, Raffaele Ornello, Matteo Foschi, Michele Romoli, Samir Abu-Rumeileh, Tsering Dolkar, Orsolya Vittay, Luke Dixon, Paul Bentley, Zoe Brown, Charles Hall, Sohaa Jamil, Harri Jenkins, Joseph Kwan, Maneesh Patel, Neil Rane, Dylan Roi, Abhinav Singh, Marius Venter, Dheeraj Kalladka, Abid Malik, Omid Halse, Simona Sacco, Soma Banerjee, Kyriakos Lobotesis
-
Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-21 Danielle Fredman, Rotem McNeil, Ofir Eldar, Avi Leader, Anat Gafter-Gvili, Tomer Avni
-
Artificial intelligence universal biomarker prediction tool J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-20 Yoshiyasu Takefuji
-
Improved visual outcomes of central retinal artery occlusion with local intra-arterial fibrinolysis beyond the conventional time window J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-19 Xuejie Li, Ting Chen, Ying Li, Chuansen Wang, Yuedan Wang, Yuwei Wan, Anhuai Yang, Xuan Xiao
-
Adherence to direct or vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a long-term observational study J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-16 Shahrzad Salmasi, Abdollah Safari, Mary A. De Vera, Tanja Högg, Larry D. Lynd, Mieke Koehoorn, Arden R. Barry, Jason G. Andrade, Marc W. Deyell, Kathy L. Rush, Yinshan Zhao, Peter Loewen
-
External validation of the CHEDDAR score for suspected pulmonary embolism in patients with SARS-CoV-2 infection in an independent cohort J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-14 Anabel Franco-Moreno, Elena Palma-Huerta, Elisa Fernández-Vidal, Elena Madroñal-Cerezo, Javier Marco-Martínez, Rodolfo Romero-Pareja, Aida Izquierdo-Martínez, Lorena Carpintero-García, José Manuel Ruiz-Giardín, Juan Torres-Macho, Cristina Lucía de Ancos-Aracil
-
Predictors of thrombosis during VV ECMO: an analysis of 9809 patients from the ELSO registry J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-14 Tia C. L. Kohs, Benjamin R. Weeder, Boris I. Chobrutskiy, Thomas Kartika, Kerry K. Moore, Owen J. T. McCarty, David Zonies, Bishoy Zakhary, Joseph J. Shatzel
-
Incidence of venous thromboembolism and predictive ability of age-adjusted international prognostic index for prediction of venous thromboembolism in Asian patients with diffuse large B-cell lymphoma J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-13 Nonthakorn Hantrakun, Phichayut Phinyo, Adisak Tantiworawit, Ekarat Rattarittamrong, Chatree Chai-Adisaksopha, Thanawat Rattanathammethee, Sasinee Hantrakool, Pokpong Piriyakhuntorn, Teerachat Punnachet, Piangrawee Niprapan, Lalita Norasetthada
-
The utility of NIRS in follow-up of patients with acute ischaemic stroke treated with IV thrombolysis and mechanical thrombectomy in the emergency department J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-12 İsmail Ataş, Gökhan Ersunan, Özlem Bỉlỉr, Özcan Yavaşỉ, Mehmet Altuntaş, Serdar Karakullukçu
-
The association of tumor-expressed REG4, SPINK4 and alpha-1 antitrypsin with cancer-associated thrombosis in colorectal cancer J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-08 Jeroen T. Buijs, Robin van Beijnum, Rayna J. S. Anijs, El Houari Laghmani, Lily Sensuk, Cas Minderhoud, Betül Ünlü, Frederikus A. Klok, Peter J. K. Kuppen, Suzanne C. Cannegieter, Henri H. Versteeg
-
Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-08 Roberta Stupia, Rosa Lombardi, Filippo Cattazzo, Mirko Zoncapè, Anna Mantovani, Leonardo De Marco, Alessandro Mantovani, Anna Ludovica Fracanzani, David Sacerdoti, Andrea Dalbeni
-
Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-12-08 Ting Zhang, Yajing Zhang, Yun Yang, Haibing Liao, Xun Li, Ran Liu, Xueqing Liu, Liqin Yang, Wei Yue
-
Association between aortic thrombi detected using non-obstructive general angioscopy and atrial fibrillation J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-11-28 Saki Mizobuchi, Keisuke Kojima, Masatsugu Miyagawa, Yudai Tanaka, Shohei Migita, Katsunori Fukumoto, Yutaka Koyama, Yasunari Ebuchi, Kurara Takahashi, Yuki Nakajima, Riku Arai, Nobuhiro Murata, Daisuke Fukamachi, Yasuo Okumura
-
Incidence and risk factors of venous thromboembolism in kidney transplantation patients: a prospective cohort study J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-11-28 Shangping Zhao, Hong Chen, Xiaoying Shi, Qiling Tan, Bo Gu
To investigate the incidence and explore the risk factors of venous thromboembolism (VTE) within 6 months after kidney transplantation. Total of 331 kidney transplant recipients were assessed by venous ultrasonography for VTE at 14 days, 1 month, 3 months, and 6 months post-transplantation. Cox forward regression were used to identify the independent risk factors of VTE. This study registration number
-
The effects of tranexamic acid on platelets in patients undergoing cardiac surgery: a systematic review and meta-analysis J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-11-14 Zhi-yao Zou, Li-xian He, Yun-tai Yao
-
HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-11-09 Nicholas B. Alana, William A. Ciurylo, Natalie Hurlock
-
Estimated glomerular filtration rate and the risk of stroke in individuals with diabetes mellitus and atrial fibrillation insight from a large contemporary population study J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-11-09 Roi Westreich, Gal Tsaban, Orit Barrett, Louise Kezerle, Meytal Avgil Tsadok, Amichay Akriv, Asaf Bachrach, Maya Leventer-Roberts, Adi Berliner Senderey, Moti Haim
-
Rural-urban differences in pulmonary embolism mortality by race-ethnicity and sex in the United States, 1999–2020 J. Thromb. Thrombolysis (IF 4.0) Pub Date : 2023-11-09 Benjamin Magod, Anuj K. Chokshi, Karlyn A. Martin, Daniel R. Schimmel, Sadiya S. Khan, Nilay S. Shah